Please login to the form below

Not currently logged in
Email:
Password:

PSPs

This page shows the latest PSPs news and features for those working in and with pharma, biotech and healthcare.

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

The investigational treatment, UCB0107, is a monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies, such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. ... UCB is already developing

Latest news

More from news
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 11 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...